After matching by age, gender, and eGFR, there were no significant differences in clinical manifestation; or serum IgA, IgM, C3 levels, and renal outcomes between patients with aMN and those with iMN in this study. The gene discussed is CD79A; the disease is adrenomyeloneuropathy.